Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: A survey of the Japan Society of Pediatric Hepatology

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 11, 2009, Pages 1256-1260

  Tajiri, Hitoshi ^a   Inui, Ayano ^b   Kiyohara, Yuki ^c   Suzuki, Mitsuyoshi ^d   Kagimoto, Seiichi ^e   Etani, Yuri ^a,c   Shimizu, Toshiaki ^d   Fujisawa, Tomoo ^b  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b Yokohama City Tobu Hospital   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

Adolescents; Children; Chronic hepatitis C; Peginterferon; Ribavirin; Virologic response

Indexed keywords

ALANINE AMINOTRANSFERASE; GENOMIC RNA; HEPATITIS C ANTIBODY; LEVOTHYROXINE; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GENOTYPE; HAIR LOSS; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; INJECTION SITE ERYTHEMA; IRRITABILITY; JAPANESE; LETHARGY; LEUKOPENIA; MALE; POLYMERASE CHAIN REACTION; POSTTRANSFUSION HEPATITIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RELAPSE; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; JAPAN; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350168055     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32832a4e97     Document Type: Article

References (27)

1. Veldt BJ, ChenW, Heathcote EJ,Wedemeyer H, Reichen J, HofmannWP, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677-684
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965 (Pubitemid 32913521)
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982
4. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al.; PEGASYS International Study Group. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355
5. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43:425-433
6. Bortolotti F, Iorio R, Resti M, Verucchi G, Giacchino R, Vegnente A, et al. Italian Observatory for the Epidemiology of Hepatitis C Virus Infection. An epidemiological survey of hepatitis C virus infection in Italian children in the decade 1990-1999. J Pediatr Gastroenterol Nutr 2001; 32:562-566
7. Resti M, Jara P, Hierro L, Azzari C, Giacchino R, Zuin G, et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol 2003; 70:373-377 (Pubitemid 36638049)
8. Etani Y, Tajiri H, Tada K, Sawada A, Kozaiwa K, Okada S, Hotta H. Molecular diagnosis and liver histology of children with mother-to-child- transmitted hepatitis C virus infection. J Pediatr 1998; 133:588
9. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341:866-870
10. Jara P, Resti M, Hierro L, Giacchino R, Barbera C, Zancan L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003; 36:275-280
11. Casiraghi MA, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, Zanetti AR. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004; 39:90-96
12. Tajiri H, Etani Y, Mushiake S, Hasegawa Y, Ozono K. Acute exacerbation of hepatitis in a boy with chronic HCV genotype-2 infection after a 9-year period of normal transaminases levels. Eur J Pediatr 2007; 166:501-502
13. Lackner H, Moser A, Deutsch J, Kessler HH, Benesch M, Kerbl R, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000; 106:E53
14. Christensson B,Wiebe T, Akesson A,Widell A. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000; 30:585-586
15. Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002; 36:1280-1284
16. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41:1013-1018
17. Jara P, Hierro L, De la Vega A, D́az C, Camarena C, Frauca E, et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008; 27:142-148
18. Tada K, Tajiri H, Kozaiwa K, Sawada A, Guo W, Okada S. Role of screening for hepatitis C virus in children with malignant disease and who undergo bone marrow transplantation. Transfusion 1997; 37:641-644
19. Okamoto H, Kobata S, Tokita H, Inoue T,Woodfield GD, Holland PV, et al. A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene. J Virol Methods 1996; 57:31-45
20. Sawada A, Tajiri H, Kozaiwa K, Guo W, Tada K, Etani Y, et al. Favorable response to lymphoblastoid interferon-alpha in children with chronic hepatitis C. J Hepatol 1998; 28:184-188
21. Miyoshi Y, Tajiri H, Okaniwa M, Terasawa S, Fujisawa T, Iizuka T, Ozono K. Hepatitis C virus infection and interferon therapy in patients with Down syndrome. Pediatr Int 2008; 50:7-11
22. Inui A, Komatsu H, Sogo T, Hashimoto T, Fujisawa T. Pegylated interferonalpha2b and ribavirin combination therapy for pediatric patients with chronic hepatitis C. Kanzo 2008; 49:386-388
23. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-999
24. Cesaro S, Rossetti F, De Moliner L, Crivellaro C, Zanesco L, Bortolotti F. Interferon for chronic hepatitis C in patients cured of malignancy. Eur J Pediatr 1994; 153:659-662
25. Mart?́nez-Bauer E, Crespo J, Romero-Gómez M, Moreno-Otero R, Solá R, Tesei N, et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 2006; 43:72-80
26. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189:964-970
27. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127:1724-1732